Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Illumina, Inc. (ILMN)

208.52   2.54 (1.23%) 12-07 16:00
Open: 206.46 Pre. Close: 205.98
High: 211.12 Low: 206.35
Volume: 933,731 Market Cap: 32,800(M)

Technical analysis

as of: 2022-12-07 4:23:11 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 270.35     One year: 290.68
Support: Support1: 203.32    Support2: 169.16
Resistance: Resistance1: 231.46    Resistance2: 248.86
Pivot: 218.41
Moving Average: MA(5): 213.59     MA(20): 222.39
MA(100): 211.42     MA(250): 265.03
MACD: MACD(12,26): -2.3     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 15.9     %D(3): 23.7
RSI: RSI(14): 42.7
52-week: High: 428  Low: 173.44
Average Vol(K): 3-Month: 1,534 (K)  10-Days: 1,082 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ILMN ] has closed above bottom band by 12.9%. Bollinger Bands are 24.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 211.22 - 212.49 212.49 - 213.72
Low: 203.34 - 204.84 204.84 - 206.27
Close: 206.23 - 208.43 208.43 - 210.54

Company Description

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

Headline News

Wed, 07 Dec 2022
Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of "Hold" by Brokerages - MarketBeat

Tue, 06 Dec 2022
Illumina loses its grip | Evaluate - Evaluate Pharma

Thu, 01 Dec 2022
RingCentral, Illumina latest Bay Area employers with layoffs - Silicon Valley Business Journal - The Business Journals

Wed, 30 Nov 2022
Illumina, Inc. (ILMN) Presents at Piper Sandler 34th Annual Healthcare Conference (Transcript) - Seeking Alpha

Tue, 29 Nov 2022
Illumina, Inc. (ILMN) Presents at Evercore ISI HealthCONx Conference (Transcript) - Seeking Alpha

Wed, 23 Nov 2022
ILMN January 2023 Options Begin Trading - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. 157 (M)
Shares Float 157 (M)
% Held by Insiders 0.3 (%)
% Held by Institutions 90.9 (%)
Shares Short 4,820 (K)
Shares Short P.Month 4,330 (K)

Stock Financials

EPS 4.44
EPS Est Next Qtl 1.02
EPS Est This Year 3.73
EPS Est Next Year 4.48
Book Value (p.s.) 42.86
Profit Margin (%) -88.4
Operating Margin (%) 4.1
Return on Assets (ttm) 0.9
Return on Equity (ttm) -48
Qtrly Rev. Growth 0.6
Gross Profit (p.s.) 20.53
Sales Per Share 29.87
EBITDA (p.s.) 3.62
Qtrly Earnings Growth 0
Operating Cash Flow 527 (M)
Levered Free Cash Flow 638 (M)

Stock Valuations

PE Ratio 46.96
PEG Ratio -5.2
Price to Book value 4.86
Price to Sales 6.97
Price to Cash Flow 62.23

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.